MycoDART
Carrollton
About MycoDART
MycoDART Inc., is the developer of molecular diagnostic tests for the rapid detection of deadly infections in very vulnerable patients such as transplant, cancer, and AIDS. Their team has dozens of years experience in business management, laboratory operations, and molecular diagnostics development. They are in the pre-launch stage for MycoDART-PCR Candida Panel. This test will identify Invasive Candidiasis infections earlier and with higher reliability than the current standard of care. As such, it will reduce mortality and cost of treatment for thousands of patients. A panel for Invasive Aspergillosis will follow.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $30.0K
- Funding stage: Seed
- Last round: Seed (Aug 2018)
- Website: mycodart.com
- Phone: (972) 947-9779
Industries & Categories
Biotechnology, Life Science, Pharmaceutical
Canonical: https://fsome.com/organization/mycodart-2241613 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.